We have developed a magnetic system for targeting cells in minimally invasive cell transplantation. Magnetically labeled MSCs (m-MSCs) with nanoscale iron particles can be guided into the desired region by magnetic force from an extracorporeal device. We reported that magnetic targeting of m-MSCs enhances cartilage repair in a mini-pig model. However, the detailed kinetics of these magnetically targeted m-MSCs remain unknown. For clinical use, this aspect should be clarifi ed from a safety standpoint. We therefore investigated the spatial and temporal distribution of the fl uorescently-labeled m-MSCs transplanted into the knee joint using in vivo fl uorescence combined with three-dimensional computed tomographic imaging in a rat model. Although the intraarticularly injected m-MSCs were spread throughout the joint cavity in the absence of magnetic force, the magnetic force caused the injected m-MSCs to accumulate around the chondral lesion. Further examinations including ex vivo imaging, histological assessments and reverse transcription polymerase chain reaction revealed that transplanted MSCs were not present in any major organs after intraarticular administration, regardless of magnetic targeting. Our data suggest that m-MSCs can be accumulated effi ciently into a chondral lesion using our magnetic targeting system, while none of the intraarticularly transplanted MSCs migrate to other major organs. Clin Trans Sci 2015; Volume 8: 467-474
Introduction
Mesenchymal stem cells (MSCs) are considered one of the most feasible cell sources for clinical application in regenerative stem cell therapy. [1] [2] [3] [4] Previously, Wakitani et al. reported the results of a clinical trial of MSC transplantation for the treatment of human cartilage defects of the knee joint in open surgery. 5 As a minimally invasive approach, some previous reports demonstrated the eff ectiveness of intraarticular injection of MSCs for the treatment of articular cartilage defects. 6, 7 However, only a small proportion of the transplanted MSCs appear likely to contribute to cartilage repair using this treatment approach. In addition, another previous study demonstrated that intraarticular injection of a large number of MSCs caused complications such as formation of loose bodies in a rat model. 8 For safe treatment, appropriate numbers of MSCs must be transplanted effi ciently into the joint. We therefore established our original cell delivery system using magnetic force called "magnetic targeting." In this system, MSCs (m-MSCs) magnetically labeled with nanoscale iron particles (ferucarbotran) can be controlled and accumulated in the desired region by the use of magnetic force. Our previous study demonstrated that an external magnetic force was able to deliver m-MSCs to a target region in a rabbit model and a fresh-frozen porcine model. 9 We also reported that m-MSCs were delivered onto degenerative human cartilage by external magnetic force and formed a cell layer in combination with extracellular matrix in vitro . 10 As a preclinical study, we studied the repair process of a chronic full-thickness cartilage defect using magnetic targeting of m-MSCs in a miniature swine model. In this study, the magnetic targeting of m-MSCs promoted the repair of the cartilage defect with hyaline-like cartilage. 11 Several previous studies have investigated the distribution of MSCs aft er intravenous administration. Th e majority of intravenously injected MSCs become trapped in the lungs at the time of fi rst-pass. [12] [13] [14] [15] [16] However, detailed kinetics of intraarticularly injected MSCs with or without magnetic targeting are still not fully understood. Before clinical application, this aspect should be clarifi ed from a safety standpoint. In this study, we therefore aimed to investigate the spatial and temporal distribution of transplanted m-MSCs into the knee joint using in vivo fl uorescence imaging combined with three-dimensional computed tomographic imaging (3D-CT) in a rat model.
Materials and Methods
Th e protocol for this study was approved by the Ethics Committee for Experimental Animals of Hiroshima University. All animal experiments were carried out under the guidelines stipulated by the Institutional Animal Care and Use Committee.
Cell culture
Human MSCs frozen at passage 2 were purchased (Lonza Japan Ltd, Tokyo, Japan) and cultured at 37°C with 5% CO 2 in MSC growth medium (MSCGM BulletKit; Lonza). Th e MSCs were passaged and split before reaching confl uence, and fourth passage human MSCs were used for all experiments.
Cell labeling (magnetic and fl uorescent labeling)
Dulbecco's modifi ed eagle medium (DMEM), 15% fetal bovine serum (FBS) and 1% antibiotic-antimycotic mixed stock solution (Nacalai Tesque, Inc., Kyoto, Japan) were equilibrated at 37°C and 5% CO 2 for at least 30 minutes. Nanoscale iron particles (ferucarbotran; 27.9 mg Fe/mL) (Fujifi lm RI Pharma Co., Ltd., Tokyo, Japan) were used for magnetic labeling of the MSCs. Ferucarbotran (35.2 μ L) was added to 10 mL of the equilibrated In Vivo Kinetics of Mesenchymal Stem Cells Transplanted into the Knee Joint in a Rat Model Using a Novel Magnetic Method of Localization medium, and the solution was mixed manually for 3 minutes. Aft er mixing, all of the solution was added to the MSCs in the culture dish, and incubated overnight to obtain magnetically labeled cells. XenoLight DiR (Perkin Elmer, Inc., Boston, MA, USA) was used for fl uorescent labeling of the m-MSCs. XenoLight DiR is a lipophilic near-infrared fl uorescent cyanine dye (1,1'-dioctadecyltetramethyl indotricarbocyanine iodide), with absorption and emission peaks at wavelengths of 748 and 780 nm. Th e magnetically labeled MSCs (m-MSCs) were washed three times with Dulbecco's phosphate buff ered saline (DPBS) and trypsinized. DiR was dissolved in ethanol, and this solution was mixed with PBS. Th e m-MSCs were incubated with 320 μg/mL DiR solution in a 37°C incubator for 30 minutes. Aft er incubation, the m-MSCs were centrifuged and washed with PBS to remove free dye in accordance with the manufacturer's instructions.
Magnetic device
To generate a magnetic fi eld in an objective space, we used a miniature superconducting bulk magnet system (Hitachi Ltd, Ibaraki, Japan). Th is system produces a magnetic fl ux density of 3.15 Tesla on the center portion of the vacuum chamber surface, and its magnetic fi eld decreases with increasing distance from the surface. A magnetic fl ux density of approximately 1.5 Tesla at a distance of 4 mm from the surface of the vacuum chambers was used in this study.
Animals and surgical procedure
Female nude rats ( F344/NJcl-rnu/rnu ) were obtained from CLEA Japan, Inc. (Tokyo, Japan). Th e rats were randomly divided into two groups of an intravenous administration group (IV; n = 3) and an intraarticular administration group ( n = 18). Furthermore, the intraarticular administration group was subdivided into a normal cartilage subgroup (NC, n = 6), a cartilage defect subgroup (CD, n = 6), and a magnet subgroup (M, n = 6). Intact rats that did not receive cell transplantation were used as the negative control group for histological examination and reverse transcription polymerase chain reaction. Th e rats were anesthetized using ketamine (100 mg/ kg) and xylazine (12 mg/kg) by intraperitoneal administration, and buprenorphine (0.1 mg/kg) by subcutaneous injection. In the intravenous administration group, m-MSCs (5.0 × 10 5 cells) in 200-μ L phosphate-buff ered saline (PBS) were injected into the caudal vein. In the intraarticular administration group, surgery was performed at 9 weeks of age with a mean body weight of 151 g (141.2-163.7). Aft er making a straight skin incision in the right knee, the femoral groove was exposed through a medial approach. In the cartilage defect subgroup and the magnet subgroup, a full-thickness articular cartilage defect 2 mm in diameter was created at the femoral groove using a power drill. Th e knee joint was irrigated with saline solution, and the capsule was tightly sutured using 5-0 nylon. In the normal cartilage subgroup, the capsule was closed without creating a cartilage defect. Th e m-MSCs (5.0 × 10 4 cells) in 50 μ L PBS were injected into the knee joint using a 29-gauge needle immediately aft er suturing the capsule. In the normal cartilage subgroup and cartilage defect subgroup, m-MSCs were administered without any magnetic control. In the magnet group, cell transplantation was performed under an external magnetic force (1.5 Tesla), and the center of the magnetic device was applied to the popliteal region for 10 minutes to accumulate the m-MSCs to the cartilage defect.
Fluorescence imaging analysis
Fluorescence imaging was performed using an IVIS spectrum CT (Perkin Elmer, Inc ). Living Image 4.3.1 software was used to analyze the images. The filters were configured at 710 nm for excitation and 760 nm for emission. Various cell numbers of fl uorescent labeled MSCs (5.0 × 10 2 to 1.0 × 10 5 ) were placed in a 96-well culture dish using serial dilution. An in vitro fl uorescence assay was performed to evaluate the detection limit of the IVIS spectrum CT system.
Rats were anesthetized before imaging using ketamine and xylazine by intraperitoneal administration except for the initial time. In vivo fl uorescence imaging was performed at fi xed intervals and ex vivo imaging was done at 72 hours after surgery for the intravenous administration group. In vivo fluorescence images and computed tomography images were acquired without sacrifi ce immediately and 1, 3, 7, 14, 21, and 28 days aft er cell transplantation to the knee for the intraarticular administration group. Fluorescence imaging tomography (FLIT) analysis which generates a 3D reconstruction of the distribution of the fl uorescent sources was performed to assess the localization of transplanted MSCs.
Rats were sacrifi ced aft er in vivo imaging at day 28, and major organs: the brain, heart, lungs, liver, spleen, kidneys and the lower limb were removed. Ex vivo fl uorescence imaging of the major organs was also carried out immediately aft er sacrifi ce. Fluorescent signal intensity was measured in the right knee area of each in vivo image by delineating the region of interest (ROI) around the cartilage defect area using 3D ROI. Th e 3D ROI was set using the same scale in all samples, and at a fi xed inclination and rotation with reference to the transepicondylar axis, posterior condylar line and anterior cortical line. Th e center of the 3D ROI was located on the articular cartilage defect of the patellar groove.
Histopathology
Th e extracted major organs were fi xed in 4% paraformaldehyde (Wako Pure Chemical Industries Ltd, Osaka, Japan) at 4°C for 24 hours. Th e tissues were then placed into 20% sucrose solution overnight. Frozen sections were prepared using Optimal Cutting Temperature (OCT) compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan). Sections of the major organs were stained with berlin blue using the conventional procedure, and nuclei were stained with nuclear fast red solution (Sigma-Aldrich Japan, Tokyo, Japan). Adjacent sections were stained for human cells by immunofl uorescence staining to detect the transplanted human MSCs. Sections were blocked with protein block, serum-free (Dako Japan Inc., Tokyo, Japan) for an hour. An antibody against human-specifi c mitochondria (EMD Millipore) was used as the primary antibody, diluted in background-reducing antibody diluent (Dako Japan). Aft er washing twice in PBS, sections were stained with primary antibody (1:100) at 4°C overnight. Sections were then washed three times for 5 minutes each time, and incubated with the secondary antibody (1:400); Alexa Fluor 568 goat antimouse IgG antibody (Life Technologies, Frederick, MD, USA) at 4°C overnight. Sections were again washed three times for 5 minutes each before counterstaining with 4,6,-diamidino-2-phenylindole (DAPI) solution for 5 minutes. After washing in PBS, coverslips were applied to the slides using fl uoromount/plus (Cosmo Bio Co., Ltd., Tokyo, Japan).
Reverse transcription-polymerase chain reaction
Reverse transcription-polymerase chain reaction (RT-PCR) was performed to analyze expression of human genes. The removed major organs; brain, heart, lungs, liver, spleen, kidneys, and synovium, were processed using RNA later (Life Technologies), and total RNA was extracted from the tissues using TRIzol (Life Technologies). Complementary DNA was obtained by reverse transcription of equal amounts of RNA per sample (200 ng) using SuperScript VILO Master Mix (Life Technologies) according to the manufacturer's protocol. PCR was performed in a total volume of 10-μ L reaction mix and contained 0.025 U/ μ L Biotaq DNA polymerase (Bioline, London, United Kingdom), 10× NH 4 reaction buff er, 0.8 mM dNTP mix, 2.5 mM MgCl 2 , 0.2 μ M of each primer, and 0.5 μ L of cDNA using a PCR thermocycler (GeneAmp PCR system 9700, Life Technologies). Matsumoto et al . previously reported the human-specific primers, and confi rmed that there was no interspecies cross-reactivity between human and rat genes. 17 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to detect the human-specifi c genes. Primer sequences were as follows: Human GAPDH (596 bp) sense 5-CTGATGCCCCCATGTTCGTC-3, antisense 5-CACCCTGTTGCTGTAG CCAAATTCG-3; rat GAPDH (320 bp) sense 5-GTGCCAGCCTCGTCTCATAGA-3, antisense 5-CGCCAGTAGACTCCACGA CAT-3. Th e amplifi cation conditions were: initial denaturation at 94°C for 1 minute, and then 35 cycles of 94°C for 30 seconds, 56°C for 1 minute, 72°C for 30 seconds. A fi nal extension step at 72°C for 7 minutes was added aft er cycling. Five microliters of each PCR product was electrophoresed at 50 V for 30 minutes in 1.5% agarose gel with 1× Tris-borate EDTA buff er, and visualized by an AE-6931GXCL Printgraph (ATTO CORPORATION, Tokyo, Japan).
Statistical analysis
All data are presented as mean and standard deviation (SD). The fluorescent signal intensity of the knee in each intraarticular transplantation group was compared by one-way analysis of variance (ANOVA) with the Tukey-Kramer method for post hoc comparison. The p values less than 0.05 were considered signifi cant. Statcel3 soft ware (OMS, Tokyo, Japan) was used for analyses.
Results

In vitro fl uorescence assay
The fluorescence intensity of the labeled MSCs changed in proportion to the cell number ( Figure 1 ). Small numbers of labeled MSCs less than 1.0 × 10 3 did not produce a detectable fl uorescent signal.
In vivo and ex vivo fl uorescence imaging
Intravenous administration group
Fluorescently labeled MSCs were administered intravenously as a positive control for migration of transplanted MSCs to major organs. Although the fl uorescent signals were not observed immediately aft er injection, they were detected in the upper abdomen 30 minutes later. Th e fl uorescent intensity gradually increased up to 48 hours aft er injection, and aft erwards decreased. Ex vivo imaging revealed that the fl uorescent signals were detected only in the lung, liver, and spleen ( Figure 2 ).
Intraarticular administration group
Th e fl uorescent signals were detected only around the right knee, and were not detectable in other parts of the body immediately aft er injection in the intraarticular administration group. Th e fl uorescent intensity peaked at 1 day aft er injection, and gradually decreased from the 3rd day in all subgroups ( Figure 3 ). In contrast, there was no detectable fl uorescent signal in the rats injected with the negative control cells without fl uorescent labeling (data not shown). Th ere were no signifi cant diff erences in fl uorescent intensity of the whole right knee joint at any time-point among the three subgroups ( Figure 3 ). Fluorescence imaging combined with 3D-CT of the right knees showed that the fl uorescent signals were diff used in the knee joint in the normal cartilage subgroup (NC) and chondral defect subgroup (CD), but were accumulated around the chondral lesion site in the magnet subgroup (M) ( Figure  4 ). The fluorescent intensity around the femoral groove was also measured by FLIT using 3D ROI. Th e fl uorescent intensity was signifi cantly stronger in the magnet group at day 3 (p = 0.038) and day 7 (p = 0.049) ( Figure 4 ). Ex vivo imaging did not reveal any fl uorescent signals in the extracted major organs including the brain, heart, lungs, liver, spleen, or kidneys, except for the right knee in all subgroups ( Figure 5 ).
Histological evaluation
Berlin blue staining
In order to detect the distribution of iron particles derived from transplanted MSCs, tissue sections of the major organs were stained with berlin blue ( Figure 6 ). Because the spleen contains endogenous iron, the spleen sections were positively stained by berlin blue in all groups, including the intact model. Apart from the spleen, some positive staining for berlin blue was observed in the lung, liver, and kidneys in the intravenous administration group. In contrast, no berlin blue dye was observed in the intraarticular administration group. Berlin blue staining revealed the absence of iron oxide derived from intraarticularly transplanted MSCs in the major organs ( Figure 6 ).
Immunofl uorescence staining
To assess the distribution of transplanted human MSCs in the major organs, tissue sections of all the major organs were immunostained with an antibody against human-specifi c mitochondrial antibodies ( Figure 7 ). In the intravenous administration group, many human-specifi c-mitochondria positive cells were observed in the lungs, and a small number of these cells were also present in the kidney, spleen, and liver. No human-derived cells were present in the major organs of the intraarticular administration group.
RT-PCR
To detect the small number of human MSCs that are undetectable by fl uorescent imaging, RT-PCR was performed using human and rat specifi c GAPDH primers ( Figure 8 ). RNA from human MSCs was used as the positive control in all groups. Tissue samples of an intact rat, including brain, heart, lungs, liver, spleen, kidneys, and synovium were used as the negative controls. In addition, the corresponding tissue samples containing 500 human MSCs were used as positive controls. Rat GAPDH was defi nitely detected in all samples other than human MSCs. In all tissue types, no human GAPDH expression could be detected except in the human MSCs in the negative control group, but were present in all organs of the positive control group. Although the band of human GAPDH could be detected in all tissues in the intravenous administration group, it was never observed in any tissue in any subgroup of the intraarticular administration group. Th ese results suggest that intraarticularly transplanted human MSCs did not translocate to the major organs.
Discussion
This study demonstrates two novel findings concerning the kinetics of MSCs transplanted into the knee. First, in vivo fl uorescent imaging combined with 3D-CT evaluation reveals that the transplanted m-MSCs accumulate around the articular cartilage defect under the infl uence of the external magnetic targeting system. Second, our data of in vivo fl uorescent imaging, histological assessments and RT-PCR suggest that none of the intraarticularly injected MSCs or iron particles migrate to the major organs regardless of the presence of an articular cartilage defect or magnetic targeting.
Assessment of in vivo fl uorescence imaging shows that the existence of an articular cartilage defect or magnetic targeting does not aff ect the fl uorescent signal intensity of the whole knee. As the rat knee is small, conventional in vivo imaging cannot show the detailed localization of fl uorescent signal in the knee. In contrast, in vivo fl uorescence imaging combined with 3D-CT shows the presence of diff use fl uorescent signals in the subgroups without magnetic targeting, and accumulation of fl uorescent signals around the chondral lesion in the group treated with magnetic targeting. In addition, fluorescent intensity around the femoral groove was strongest in the group treated by intraarticular injection with magnetic targeting up to 7 days aft er injection. Th ese fi ndings suggest that our magnetic targeting system not only accumulates the intraarticularly injected MSCs but also causes the majority of them to remain around the chondral lesion.
From the point of view of safety, the greatest cause for concern associated with transplantation of m-MSCs is the transfer of injected MSCs and iron particles to the major organs. Migration of a large number of MSCs might induce infarction of major organs, and iron overload might cause organ damage especially in the liver and heart due to free radical production. 18 In this study, in vivo fl uorescence imaging showed the absence of fl uorescent signals in any area of the body except for the right knee joint at several time points up to 28 days aft er intraarticular injection of fl uorescent labeled MSCs. Additionally, ex vivo fl uorescence imaging, histological assessments and RT-PCR revealed that no transplanted human MSCs or iron particles were present in the major organs at 28 days aft er intraarticular injection. In vivo fl uorescence imaging is useful in that it can be constantly assessed in living animals. However, it has limited detection sensitivity. Th e results of our assessment of the sensitivity of fl uorescence imaging suggest that it cannot detect fewer than 1,000 MSCs. Th erefore, histological evaluation and RT-PCR were performed using tissue samples of major organs in order to detect small numbers of human MSCs. Th ese data in this study strongly support the hypothesis that magnetic targeting of MSCs is a safe treatment.
Th e management of articular cartilage defects is one of the most challenging clinical problems. Th e goal of surgical repair is to achieve the regeneration of hyaline cartilage. 19, 20 A variety of techniques have been used to treat cartilage defects such as bone marrow stimulation, osteochondral graft and autologous chondrocyte implantation. MSC-based therapies for the regeneration of cartilage have gained popularity over the last few years. 7 Transplantation or injection of MSCs into cartilage defects has been attempted in preclinical and clinical studies. 21 No intraarticular complications were observed during followup, and MSCs have safely been applied in a number of clinical trials in humans. 22 MSCs are a promising source of stem cells for tissue repair and gene therapy because of their relative ease of expansion in culture, and their immunologic characteristics. 23 MSCs can diff erentiate into several diff erent cell types in vitro , and act through paracrine mechanisms that might play a role in stimulation of the regenerative process. 24 However, low cell survival and engraft ment rate have been the main limiting factors of stem cell-based therapies, 25 and improvement of cell delivery methods is necessary to maximize the regenerative potential of MSCs. 26 To address this issue, we developed an original magnetic cell delivery system to expeditiously localize cells to the target site, and have previously demonstrated that m-MSCs delivered using this system regenerated articular cartilage, bone, muscle, and spinal cord. 9,11,27-30 Kamei et al. showed that m-MSCs delivered using our system promote early regeneration of the cartilage layer and regenerate cartilage in a porcine full thickness cartilage defect model with hyaline-like cartilage. 11 Effi cacy of m-MSCs combined with a magnetic cell delivery system for articular cartilage defect repair were thus confi rmed in an animal model. This procedure is progressing to the preliminary stages of clinical use. For the realization of clinical use, it is important to confi rm the safety of intraarticular transplanted m-MSCs. Th e in vivo kinetics of systemically administered MSCs have already been reported in various studies. Intravenously injected MSCs were mainly trapped in the lungs. 31, 32 Th e homing of MSCs to injured areas was impeded by cell entrapment in the lungs in a myocardial infarction model. 33 MSCs that were injected into the left ventricle evaded trapping in the capillary beds of the lung, and instead were dispersed to the heart, lungs, and kidney glomeruli. 14 Th e highest levels of engraft ment were observed in the pancreas and kidney in a diabetic model. 34 Conversely, in vivo kinetics of intraarticularly transplanted MSCs have remained unclear. Th erefore, our fi ndings in the present study are helpful in demonstrating that clinical treatment for articular cartilage defects using MSC transplantation with magnetic targeting can be performed safely.
Conclusion
Th is study showed that the transplanted m-MSCs accumulate around the articular cartilage defect under the infl uence of the external magnetic targeting system, and none of the intraarticularly injected MSCs or iron particles migrate to the major organs. Th e fi ndings in this study support that the clinical application of our novel cell targeting system using m-MSCs and a magnetic device can be performed eff ectively and safely. 
